Annovis Bio Receives Institutional Review Board Approval to Initiate Phase 2 Study
BERWYN, PA — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, reported that it has received …
Read More